Patents by Inventor Charles Conrad

Charles Conrad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Esters of 2-deoxy-monosaccharides with anti proliferative activity
    Patent number: 11925654
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: March 12, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • ESTERS OF 2-DEOXY-MONOSACCHARIDES WITH ANTI PROLIFERATIVE ACTIVITY
    Publication number: 20220023326
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Application
    Filed: June 4, 2021
    Publication date: January 27, 2022
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)
    Publication number: 20210301264
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Application
    Filed: June 11, 2021
    Publication date: September 30, 2021
    Applicants: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Juan Fueyo-Margareto, Candelaria Gomez-Manzano, Charles Conrad, Alfred W.K. Yung, Hong Jiang
  • Adenovirus and immunomodulator combination therapy
    Patent number: 11090344
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: August 17, 2021
    Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Juan Fueyo-Margareto, Candelaria Gomez-Manzano, Charles Conrad, W. K. Alfred Yung, Hong Jiang
  • Biomarkers and combination therapies using oncolytic virus and immunomodulation
    Patent number: 11065285
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: July 20, 2021
    Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Jr., Candelaria Gomez-Manzano, W.K. Alfred Yung, Amy Heimberger
  • TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS
    Publication number: 20210213079
    Abstract: The present disclosure involves compositions and methods for treating brain cancers having mutations in the retinoblastoma (Rb) pathway using an oncolytic adenovirus comprising an alteration in the Rb binding site of E1A, and a targeting motif inserted in the Ad fiber protein. The adenovirus is able to kill the tumor cells without harming cells with a wild-type retinoblastoma pathway.
    Type: Application
    Filed: March 5, 2021
    Publication date: July 15, 2021
    Inventors: Juan FUEYO-MARGARETO, Candelaria GOMEZ-MANZANO, Charles CONRAD, Fred LANG, JR., W.K. Alfred YUNG, Frank TUFARO
  • Esters of 2-deoxy-monosaccharides with anti proliferative activity
    Patent number: 11026960
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 8, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION
    Publication number: 20200330533
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 22, 2020
    Inventors: Frank TUFARO, Charles CONRAD, Juan FUEYO-MARGARETO, Frederick LANG, JR., Candelaria GOMEZ-MANZANO, W.K. Alfred YUNG, Amy HEIMBERGER
  • BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION
    Publication number: 20190269744
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Application
    Filed: March 5, 2019
    Publication date: September 5, 2019
    Inventors: Frank TUFARO, Charles CONRAD, Juan FUEYO-MARGARETO, Frederick LANG, JR., Candelaria GOMEZ-MANZANO, W.K. Alfred YUNG, Amy HEIMBERGER
  • ESTERS OF 2-DEOXY-MONOSACCHARIDES WITH ANTI PROLIFERATIVE ACTIVITY
    Publication number: 20190224225
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 25, 2019
    Inventors: Waldemar PRIEBE, Marcin CYBULSKI, Izabela FOKT, Stanislaw SKORA, Charles CONRAD, Timothy MADDEN
  • DNA binding agents with a minor groove binding tail
    Patent number: 10358439
    Abstract: Provided herein are compounds which intercalate into the DNA of a cell and are capable of crossing the blood brain barrier of a formula provided herein. Pharmaceutical compositions of the compounds and methods of treating cancer, for example brain, lung, or pancreatic cancer, are also provided herein.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: July 23, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Liwei Guo, Arkadiusz Kazimierski, Izabela Fokt, Charles Conrad, Timothy Madden
  • ADENOVIRUS AND IMMUNOMODULATOR COMBINATION THERAPY
    Publication number: 20190201462
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Application
    Filed: May 30, 2017
    Publication date: July 4, 2019
    Inventors: Frank TUFARO, Juan FUEYO-MARGARETO, Candelaria GOMEZ-MANZANO, Charles CONRAD, W.K. Alfred YUNG, Hong JIANG
  • ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)
    Publication number: 20190093085
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Application
    Filed: June 27, 2018
    Publication date: March 28, 2019
    Applicants: DNATRIX, INC., THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Juan Fueyo-Margareto, Candelaria Gomez-Manzano, Charles Conrad, Alfred W.K. Yung, Hong Jiang
  • Biomarkers and combination therapies using oncolytic virus and immunomodulation
    Patent number: 10238698
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 26, 2019
    Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Jr., Candelaria Gomez-Manzano, W. K. Alfred Yung, Amy Heimberger
  • Esters of 2-deoxy-monosacharides with anti proliferative activity
    Patent number: 10201554
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 12, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Oncolytic adenovirus armed with therapeutic genes
    Patent number: 10080774
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: September 25, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano, W. K. Alfred Yung, Charles A. Conrad, Frederick F. Lang, Jr.
  • DNA BINDING AGENTS WITH A MINOR GROOVE BINDING TAIL
    Publication number: 20180251454
    Abstract: Provided herein are compounds which intercalate into the DNA of a cell and are capable of crossing the blood brain barrier of a formula provided herein. Pharmaceutical compositions of the compounds and methods of treating cancer, for example brain, lung, or pancreatic cancer, are also provided herein.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 6, 2018
    Applicant: Board of Regents, The University of Texas System
    Inventors: Waldemar PRIEBE, Liwei GUO, Arkadiusz KAZIMIERSKI, Izabela FOKT, Charles CONRAD, Timothy MADDEN
  • Adenovirus Expressing Immune Cell Stimulatory Receptor Agonist(s)
    Publication number: 20160289645
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Application
    Filed: November 21, 2014
    Publication date: October 6, 2016
    Applicants: DNATRIX, INC., THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYST EM
    Inventors: Frank TUFARO, Juan FUEYO-MARGARETO, Candelaria GOMEZ-MANZANO, Charles CONRAD, Alfred W.K. YUNG, Hong JIANG
  • ESTERS OF 2-DEOXY-MONOSACHARIDES WITH ANTI PROLIFERATIVE ACTIVITY
    Publication number: 20160184336
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Application
    Filed: April 4, 2014
    Publication date: June 30, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Golf club holder
    Patent number: D757874
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: May 31, 2016
    Inventor: Ryan Charles Conrad